On November 5, 2020 Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported that studies sponsored by Janssen Research & Development, LLC (Janssen) evaluating subcutaneous (SC) daratumumab utilizing ENHANZE will be the subject of presentations at the upcoming American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition taking place virtually December 5-8, 2020 (Press release, Halozyme, NOV 5, 2020, View Source [SID1234570017]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Primary data from the Phase 3 APOLLO study of SC daratumumab in combination with pomalidomide and dexamethasone (D-Pd) in patients with multiple myeloma who have received one or more prior lines of therapy (Abstract #412) will be the subject of an oral presentation and official ASH (Free ASH Whitepaper) Press Program (Sunday, December 6 3:00 p.m. ET).

Results from the Phase 3 ANDROMEDA study of SC daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) in patients with light chain AL amyloidosis (Abstract #552) will be the subject of an oral presentation (Monday, December 7 11:15 a.m. ET). The ANDROMEDA study will also be the subject of four poster presentations (Abstracts #1392, #1640, #1409 and #2305).